Can survival of systemic lupus erythematosus be further improved?

APLAR Journal of Rheumatology

Volumn 8, Issue 3, 2005, Pages 159-164

  Mok, C C ^a  

^a TUEN MUN HOSPITAL   (Hong Kong)

Author keywords

Asian; Chinese; Epidemiology; Morbidity; Mortality; Outcome

Indexed keywords

ABETIMUS; ACETYLSALICYLIC ACID; AZATHIOPRINE; BELIMUMAB; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID DERIVATIVE; CYCLOPHOSPHAMIDE; EPRATUZUMAB; GONADORELIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; INTERLEUKIN 10 ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARATHYROID HORMONE; PREDNISOLONE; RALOXIFENE; RITUXIMAB; VITAMIN D;

AMENORRHEA; ATHEROSCLEROSIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG DOSE REGIMEN; DRUG MEGADOSE; EARLY DIAGNOSIS; EARLY MENOPAUSE; FRAGILITY FRACTURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUPUS ERYTHEMATOSUS NEPHRITIS; MORTALITY; OPPORTUNISTIC INFECTION; OVARY DISEASE; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOEMBOLISM; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA IN SITU;

EID: 29144527067     PISSN: 02190494     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1479-8077.2005.00153.x     Document Type: Review

References (50)

1. Merrel M, Shulman LE (1955) Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. J Chronic Dis 1, 12-32.
2. Cervera R, Khamashta MA, Font J, et al. (2003) European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1000 patients. Medicine (Baltimore) 82, 299-308.
3. Mok CC, Mak A, Chu WP, To CH, Wong SN (2005) Long term survival of southern Chinese patients with systemic lupus erythematosus: a prospective study of all age groups. Medicine (Baltimore) 84, 218-24.
4. Peschken CA, Esdaile JM (2000) Systemic lupus erythematosus in North American Indians: a population based study. J Rheumatol 27, 1884-91.
5. Stahl-Hallengren C, Jonsen A, Nived O, Sturfelt G (2000) Incidence studies of systemic lupus erythematosus in Southern Sweden: increasing age, decreasing frequency of renal manifestations and good prognosis. J Rheumatol 27, 685-91.
6. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J (1995) Mortality studies in systemic lupus erythematosus. Results from a single center. I. Causes of death. J Rheumatol 22, 1259-64.
7. Urowitz MB, Gladman DD, Abu-Shakra M, Farewell VT (1997) Mortality studies in systemic lupus erythematosus. Results from a single center. III. Improved survival over 24 years. J Rheumatol 24, 1061-5.
8. Borchers AT, Keen CL, Shoenfeld Y, Gershwin ML (2004) Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev 3, 423-53.
9. Petri M (2002) Epidemiology of systemic lupus erythematosus. Best Pract Res Clin Rheumatol 16, 847-58.
10. Wallace DJ (2002) Management of lupus erythematosus: recent insights. Curr Opin Rheumatol 14, 212-9.
11. Urowitz MB, Bookman AA, Koehler BL, Gordon DA, Smythe HA, Ogryzlo MA (1976) The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 60, 221-5.
12. Bjornadal L, Yin L, Granath F, Klareskog L, Ekbom A (2004) Cardiovascular disease a hazard despite improved prognosis in patients with systemic lupus erythematosus: results from a Swedish population based study 1964-95: J Rheumatol 31, 713-9.
13. Mok CC, Lee KW, Ho CTK, Lau CS, Wong RWS (2000) A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology (Oxford) 39, 399-406.
14. Ward MM (1999) Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 42, 338-46.
15. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. (2001) Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 44, 2331-7.
16. Manzi S, Meilahn EN, Rairie JE, et al. (1997) Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145, 408-15.
17. Svenungsson E, Jensen-Urstad K, Heimburger M, et al. (2001) Risk factors for cardiovascular disease in systemic lupus erythematosus. Circulation 104, 1887-93.
18. Petri M, Roubenoff R, Dallal GE, Nadeau MR, Selhub J, Rosenberg IH (1996) Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 348, 1120-4.
19. von Scheven E, Glidden DV, Elder ME (2002) Anti-beta2-glycoprotein I antibodies in pediatric systemic lupus erythematosus and antiphospholipid syndrome. Arthritis Rheum 47, 414-20.
20. Ohlenschlaeger T, Garred P, Madsen HO, Jacobsen S (2004) Mannose-binding lectin variant alleles and the risk of arterial thrombosis in systemic lupus erythematosus. N Engl J Med 351, 260-7.
21. Toloza SM, Uribe AG, Mcgwin G Jr, et. al. (2004) Lumina Study Group. Systemic lupus erythematosus in a multi-ethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 50, 3947-57.
22. Kao AH, Sabatine JM, Manzi S (2003) Update on vascular disease in systemic lupus erythematosus. Curr Opin Rheumatol 15, 519-27.
23. Asanuma Y, Oeser A, Shintani AK, et al. (2003) Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 349, 2407-15.
24. Roman MJ, Shanker BA, Davis A, et al. (2003) Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 349, 2399-406.
25. Mok CC, Tang SSK, To CH, Petri MA (2005) Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic Groups. Arthritis Rheum 52, 2774-82.
26. Mok CC, Ho CT, Wong RW, Lau CS (2003) Damage accrual in southern Chinese patients with systemic lupus erythematosus. J Rheumatol 30, 1513-9.
27. Nived O, Jonsen A, Bengtsson AA, Bengtsson C, Sturfelt G (2002) High predictive value of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for survival in systemic lupus erythematosus. J Rheumatol 29, 1398-400.
28. Alarcon GS, Mcgwin G Jr, Bastian HM, et al. (2001) Systemic lupus erythematosus in three ethnic Groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group. Arthritis Rheum 45, 191-202.
29. Ciruelo E, de la Cruz J, Lopez I, Gomez-Reino JJ (1996) Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis Rheum 39, 2028-34.
30. Bruce IN, Gladmann DD, Urowitz MB (2000) Factors associated with refractory renal disease in patients with systemic lupus erythematosus: the role of patient non-adherence. Arthritis Care Res 13, 406-8.
31. Petri M, Perez-Gutthann S, Longenecker JC, Hochberg M (1991) Morbidity of systemic lupus erythematosus: role of race and socioeconomic status. Am J Med 91, 345-53.
32. Barr RG, Seliger S, Appel GB, et al. (2003) Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol Dial Transplant 18, 2039-46.
33. Fiehn C, Hajjar Y, Mueller K, Waldherr R, Ho AD, Andrassy K (2003) Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann Rheum Dis 62, 435-9.
34. Gourley MF, Austin HA 3rd, Scott D et al. (1996) Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med 125, 549-57.
35. Petri M (1998) Infection in systemic lupus erythematosus. Rheum Dis Clin North Am 24, 423-56.
36. Mok CC, Ho CTK, Chan KW, Lau CS, Wong RWS (2002) Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum 46, 1003-13.
37. Houssiau FA, Vasconcelos C, D'Cruz D, et al. (2004) Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 50, 3934-40.
38. Jayne D, Rasmussen N, Andrassy K, et al. European Vasculitis Study Group. (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349, 36-44.
39. Abu-Shakra M, Zalmanson S, Neumann L, Flusser D, Sukenik S, Buskila D (2000) Influenza virus vaccination of patients with systemic lupus erythematosus: effects on disease activity. J Rheumatol 27, 1681-5.
40. Chan TM, Tse KC, Tang CS, Mok MY, Li FK (2005) Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 16, 1076-84.
41. Contreras G, Pardo V, Leclercq B, et al. (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350, 971-80.
42. Zandman-Goddard G, Shoenfeld Y (2004) Therapy with biologic agents in systemic lupus erythematosus. APLAR J Rheumatol 7, 79-82.
43. Mok CC, Lau CS, Wong RWS (1998) Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 41, 831-7.
44. Somers EC, Marder W, Christman GM, et al. (2005) Use of a gonadotropin-releasing hormone analog for protection against premature ovarian failure during cyclophosphamide therapy in women with severe lupus. Arthritis Rheum 52, 2761-7.
45. Ramsey-Goldman R, Dunn JE, Huang CF, et al. (1999) Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum 42, 882-90.
46. Yee CS, Crabtree N, Skan J, et al. (2005) Prevalence and predictors of fragility fractures in systemic lupus erythematosus. Ann Rheum Dis 64, 111-3.
47. Mok CC, Mak A, Ma KM (2005) Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus 14, 106-12.
48. Kanis JA, Johnell O, Black DM, et al. (2003) Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 33, 293-300.
49. Barrett-Connor E, Grady D, Sashegyi A, et al. (2002) Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287, 847-57.
50. Mok CC, To CH, Mak A, Ma KM (in press) Raloxifene for postmenopausal women with systemic lupus erythematosus: a pilot randomized controlled study. Arthritis Rheum in press.